Triple negative breast cancers (TNBC) account for ~15–20% of BC cases and refer to a heterogenous group of BC that lacks expression of estrogen receptor (ER)α, progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) [2]. This evidence concerns the gene PGR and triple-negative breast carcinoma.